ELUFREZ Trademark
Trademark Overview
On Thursday, March 7, 2019, a trademark application was filed for ELUFREZ with the United States Patent and Trademark Office. The USPTO has given the ELUFREZ trademark a serial number of 79255628. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, May 29, 2026. This trademark is owned by Glaxo Group Limited. The ELUFREZ trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines
General Information
| Serial Number | 79255628 |
| Word Mark | ELUFREZ |
| Filing Date | Thursday, March 7, 2019 |
| Status | 709 - CANCELLED - SECTION 71 |
| Status Date | Friday, May 29, 2026 |
| Registration Number | 5905903 |
| Registration Date | Tuesday, November 12, 2019 |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, August 27, 2019 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | F - NOT AVAILABLE |
| Class Status Date | Friday, May 29, 2026 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Glaxo Group Limited |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Glaxo Group Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Glaxo Group Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
Trademark Events
| Event Date | Event Description |
| Thursday, March 28, 2019 | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB |
| Wednesday, April 3, 2019 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, April 3, 2019 | ASSIGNED TO EXAMINER |
| Friday, April 5, 2019 | NON-FINAL ACTION WRITTEN |
| Saturday, April 6, 2019 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Tuesday, April 9, 2019 | APPLICATION FILING RECEIPT MAILED |
| Monday, April 29, 2019 | REFUSAL PROCESSED BY MPU |
| Monday, April 29, 2019 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Friday, May 17, 2019 | REFUSAL PROCESSED BY IB |
| Friday, July 12, 2019 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, July 18, 2019 | ASSIGNED TO LIE |
| Thursday, July 18, 2019 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, July 18, 2019 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, July 23, 2019 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, August 7, 2019 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Wednesday, August 7, 2019 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, August 7, 2019 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Friday, August 23, 2019 | NOTIFICATION PROCESSED BY IB |
| Tuesday, August 27, 2019 | PUBLISHED FOR OPPOSITION |
| Tuesday, August 27, 2019 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, November 12, 2019 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, February 12, 2020 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Friday, March 6, 2020 | FINAL DISPOSITION PROCESSED |
| Friday, March 6, 2020 | FINAL DISPOSITION NOTICE SENT TO IB |
| Friday, April 24, 2020 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Sunday, July 23, 2023 | CHANGE OF NAME/ADDRESS REC'D FROM IB |
| Thursday, May 2, 2024 | INTERNATIONAL REGISTRATION RENEWED |
| Tuesday, November 12, 2024 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| Thursday, June 5, 2025 | NEW REPRESENTATIVE AT IB RECEIVED |
| Friday, May 29, 2026 | CANCELLED SECTION 71 |
